MSH|^~\&|^2.16.840.1.113883.3.72.5.20^ISO|^2.16.840.1.113883.3.72.5.21^ISO||^2.16.840.1.113883.3.72.5.23^ISO|20110601140928-0800||ORU^R01^ORU_R01|LRI_4.2_2.1-GU_FRN|D|2.5.1|||AL|NE|||||LRI_Common_Component^^2.16.840.1.113883.9.16^ISO~LRI_GU_Component^^2.16.840.1.113883.9.12^ISO~LRI_FRN_Component^^2.16.840.1.113883.9.84^ISOPID|1||PATID1234^^^&2.16.840.1.113883.3.72.5.30.2&ISO^MR||Jones^William^A^^^^L||19610615|M||2106-3^White^HL70005||||||||PATID1234^^^&2.16.840.1.113883.3.72.5.30.2&ISO^MRORC|RE|ORD723222-4^^2.16.840.1.113883.3.72.5.24^ISO|R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|GORD874255^^2.16.840.1.113883.3.72.5.24^ISO||||||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPIOBR|1|ORD723222-4^^2.16.840.1.113883.3.72.5.24^ISO|R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^^^Stool Culture|||20110530123551-0800|||||||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI||||||20110601140428-0800|||F|||10092000194^Hamlin^Pafford^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPIOBX|1|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|1|103429008^Enterohemorrhagic Escherichia coli, serotype O157:H7^SCT^^^^^^Shiga toxin producing E. coli O157:H7 isolated|||A|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTNTE|1||Susceptibility testing for E.coli is not performed, because antibiotics should not be used to treat this infection. There is no evidence that treatment with antibiotics is helpful, and taking antibiotics may increase the risk of hemolytic-uremic syndrome (HUS). Antidiarrheal agents like Imodium® may also increase that risk. Non-specific supportive therapy, including hydration, is important. OBX|2|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|2|398567006^Salmonella I, group O:4^SCT^^^^^^Salmonella I, group O:4 isolated|||A|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTNTE|1||Salmonella gastrointestinal infections usually resolve in 5-7 days and most do not require treatment other than oral fluids. Persons with severe diarrhea may require rehydration with intravenous fluids. Antibiotic therapy can prolong the duration of excretion of non-typhoidal Salmonella and is recommended only for patients with severe illness (e.g., those with severe diarrhea, high fever, bloodstream infection, or who need hospitalization) or those at risk of severe disease or complications, including young infants, older adults (over 65 years old) and immunocompromised persons. Antibiotic resistance is increasing among some Salmonella bacteria; therefore, susceptibility testing can help guide appropriate therapy. Choices for antibiotic therapy for severe infections include fluoroquinolones, third-generation cephalosporins, and ampicillin (for susceptible infections).OBX|3|CWE|625-4^Bacteria identified in Stool by Culture^LN^^^^^^Stool Culture|3|85729005^Shigella flexneri^SCT^^^^^^Shigella flexneri isolated|||A|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTNTE|1||Antibiotic treatment is recommended for patients with severe disease, bloody diarrhea, or compromised immune systems. Resistance to traditional first-line drugs like ampicillin and trimethoprim-sulfamethoxazole is common, and resistance to some other antibiotics is increasing. With this in mind, antibiotic susceptibility testing can help guide appropriate therapy. When an ampicillin- or trimethroprim-sulfamethoxazole-resistant strain is isolated, choices for therapy include fluoroquinolones, ceftriaxone, and azithromycin. SPM|1|S-2015-66&&2.16.840.1.113883.3.72.5.24&ISO^S-9911-33&&2.16.840.1.113883.3.72.5.25&ISO||119339001^Stool specimen^SCT^^^^^^Stool|||||||||||||20110530123551-0800ORC|RE||R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|GORD874255^^2.16.840.1.113883.3.72.5.24^ISO||||||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI|||||||||||||||||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^^^Stool CultureOBR|2||R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|50545-3^Bacterial susceptibility panel in Isolate by Minimum inhibitory concentration (MIC)^LN^^^^^^Bacteria susceptibility|||20110530123551-0800||||G|||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI||||||20110601140428-0800|||F|625-4&Bacteria identified in Stool by Culture&LN&&&&&&Stool Culture^2||10092000194^Hamlin^Pafford^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI|ORD723222-4&&2.16.840.1.113883.3.72.5.24&ISO^R-783274-4&&2.16.840.1.113883.3.72.5.25&ISO|||||||||||||||||||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^^^Stool CultureOBX|1|SN|28-1^Ampicillin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|<^0.06|ug/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTOBX|2|SN|267-5^Gentamicin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^0.05|ug/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTOBX|3|SN|185-9^Ciprofloxacin [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^0.05|ug/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLTORC|RE||R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|GORD874255^^2.16.840.1.113883.3.72.5.24^ISO||||||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI|||||||||||||||||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^^^Stool CultureOBR|3||R-783274-4^^2.16.840.1.113883.3.72.5.25^ISO|50545-3^Bacteria susceptibility^LN^^^^^^Bacteria susceptibility|||20110530123551-0800||||G|||||5742200012^Radon^Nicholas^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI||||||20110601140428-0800|||F|625-4&Bacteria identified in Stool by Culture&LN&&&&&&Stool Culture^3||10092000194^Hamlin^Pafford^^^^^^&2.16.840.1.113883.4.6&ISO^L^^^NPI|ORD723222-4&&2.16.840.1.113883.3.72.5.24&ISO^R-783274-4&&2.16.840.1.113883.3.72.5.25&ISO|||||||||||||||||||||625-4^Bacteria identified in Stool by Culture^LN^3456543^CULTURE STOOL^99USL^^^Stool CultureOBX|2|SN|516-5^Trimethoprim+​Sulfamethoxazole [Susceptibility] by Minimum inhibitory concentration (MIC)^LN|1|^2^/^38|ug/mL^^UCUM||S|||F|||20110530123551-0800|||||20110601130655-0800||||Century Hospital^^^^^&2.16.840.1.113883.4.7&ISO^XX^^^24D9871327|2070 Test Park^^Los Angeles^CA^90067^^L|2343242^Knowsalot^Phil^J.^^^^^&2.16.840.1.113883.3.72.5.30.1&ISO^L^^^DN||||RSLT